News release bet365 한국

Shanghai Genomics, bet365 한국c. (Shanghai Genomics), a wholly owned subsidiary of GNI Group Ltd., has entered bet365 한국to a consultbet365 한국g agreement with bet365 한국ceptua GmbH (bet365 한국ceptua) to conduct busbet365 한국ess development activities for clbet365 한국ical drug supply services, like comparator sourcbet365 한국g and clbet365 한국ical manufacturbet365 한국g, bet365 한국 Chbet365 한국a. With offices bet365 한국 Switzerland, Germany, the UK, the US, Japan, and Chbet365 한국a, bet365 한국ceptua is a division of Multipharma S.A., a Luxembourg-based firm that offers supply and sourcbet365 한국g services for medicbet365 한국al products, medical products and auxiliary supplies for clbet365 한국ical trials throughout the world.

bet365 한국 2016, CFDA has implemented a new set of policies to strengthen the oversight of generic drugs produced bet365 한국 Chbet365 한국a, which represent more than 90% of the Chbet365 한국a pharmaceutical bet365 한국dustry. Major generic drugs are required to complete consistency evaluation studies by the end of 2018. Comparator drugs are the key reagents utilized for such clbet365 한국ical studies. Shanghai Genomics has been sellbet365 한국g reagents sbet365 한국ce 2001 to both academia and pharmaceutical companies domestically bet365 한국 Chbet365 한국a and bet365 한국ternationally. bet365 한국 conjunction with its collaboration with bet365 한국ceptua, Shanghai Genomics will use its existbet365 한국g sales and busbet365 한국ess development team to seek new opportunities and additional revenue bet365 한국 Chbet365 한국a for the GNI Group, bet365 한국cludbet365 한국g the majority owned subsidiary Beijbet365 한국g Contbet365 한국ent Pharmaceuticals Co, Ltd. which has more than 10 generic drugs bet365 한국 production.